<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">NM</journal-id><journal-title-group><journal-title>Neuroscience &amp; Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-2912</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/nm.2011.24049</article-id><article-id pub-id-type="publisher-id">NM-9081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  The Neuroinflammatory Response Induced by PAF Can Be Attenuated by BN52021 Administration
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>uizhang</surname><given-names>Han</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jinjia</surname><given-names>Hu</given-names></name><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guojun</surname><given-names>Su</given-names></name></contrib></contrib-group><author-notes><corresp id="cor1">* E-mail:<email>jjhu2609@126.com(JH)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>12</month><year>2011</year></pub-date><volume>02</volume><issue>04</issue><fpage>370</fpage><lpage>375</lpage><history><date date-type="received"><day>October</day>	<month>6th,</month>	<year>2011</year></date><date date-type="rev-recd"><day>November</day>	<month>17th,</month>	<year>2011</year>	</date><date date-type="accepted"><day>November</day>	<month>29th,</month>	<year>2011.</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective: The purpose of this study was to determine whether BN52021, a platelet-activation factor receptor (PAFR) antagonist, could provide neuroprotection from the cytotoxic effects of PAF-induced neuroinflammation. Methods: The inflammagen platelet-activation factor (PAF) was first added to cultured PC12 cells. BN52021 was then added 24 hours later, survival rate and rate of apoptosis of the PC12 cells was determined by the MTT method and flow cytometry. In addition, PAF was injected into the fourth ventricle, and the effect of BN52021 administration was determined in rats. Results: PAF induced apoptosis in cultured PC12 cells, and BN52021 administration protected PC12 cells from PAF-induced apoptosis. When PAF is injected into the fourth ventricle, PAF induces acute neuroinflammation in the whole brain of rats. Acute PAF infusions also impaired spatial recognition in rats. The peripheral administration of BN52021 (i.p.) protected the rats from this impairment in spatial recognition. Conclusion: The PAFR antagonist BN52021 provides neuroprotection from the cytotoxic effects induced by the inflamagen PAF.
 
</p></abstract><kwd-group><kwd>Neuroinflammation</kwd><kwd> Spatial Memory</kwd><kwd> Platelet-Activation Factor</kwd><kwd> BN52021</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Brain injury is a common disease that threatens human health [<xref ref-type="bibr" rid="scirp.9081-ref1">1</xref>]. Brain injury can be divided into types including primary and secondary [<xref ref-type="bibr" rid="scirp.9081-ref2">2</xref>]. Secondary brain injury or acute neuroinflammation occurs within hours or days after a brain injury, and this brain injury consists of neuron damage and nervous system dysfunction that is associated with specific biochemical processes. Learning and memory deficits represent common sequelae of secondary injury to the brain, and could seriously affect the quality of life of patients [<xref ref-type="bibr" rid="scirp.9081-ref3">3</xref>]. Various neuroinflammatory factors play an important role in secondary brain damage, including interleukin1-α, interleukin1-β, prostaglandins, tumor necrosis factor, etc. PAF represents one of the strongest inflammatory factors in the central nervous system. Previous studies have found that a marked rise in PAF and prostaglandin levels were associated with brain inflammation [<xref ref-type="bibr" rid="scirp.9081-ref4">4</xref>]. Therefore, PAF is the key link in the regulation of neuroinflammation. The purpose of the current study was to investigate whether BN52021, PAFR antagonist, could provide neuroprotection from the cytotoxic effects induced by PAF in vitro and in vivo.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Cell Culture</title><p>PC12 cells were cultured in MEM/F-12 (1:1) medium (Invitrogen, USA) supplemented with 10% fetal calf serum (FCS, Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin. The PC12 cells were cultured in a humidifed atmosphere containing 5% CO<sub>2</sub> at 37˚C. When the cells reached the proper confluence, they were placed into a serum-free medium. The cells were incubated with PAF (0.1, 0.3, 0.6 μmol/L) for 24 hours or incubated with PAF (0.3 μmol/L) for three hours. Without changing the culture medium, the cells were then treated with BN52021 (Long He Co.; low dose group: 1 mg/L; high dose group: 5 mg/L) for an additional 48 hours.</p></sec><sec id="s2_2"><title>2.2. MTT Assay of Cell Viability</title><p>PC12 cells were plated at 5 &#215; 10<sup>4</sup> cells/well (200 μl) into 96 well plates, and allowed to adhere and grow until they reached the required confluence. After drug treatment, the survival of cells was determined by MTT assay. Briefy, after incubation with 20 μl MTT (5 mg/ml, Sigma) at 37˚C for 3 hours, living cells containing MTT formazon crystals were made soluble in 200 μl dimethylsulfoxide (DMSO, Sigma). The absorbance of each well was measured using a microculture plate reader with a test wave length of 570 nm and a reference wave length of 655 nm. The light absorption value was measured to determine formazan absorption.</p></sec><sec id="s2_3"><title>2.3. Measurement of Apoptosis by Flow Cytometry</title><p>To determine whether PAF-triggered cell death was apoptotic, we measured cell apoptosis using an AnnexinVFITC Apoptosis Detection Kit (BD Pharmingen, USA) according to the manufacturer’s instructions. Briefy, the cells were plated at a density of 5 &#215; 10<sup>5</sup> cells/ml into six well plates, and cultured until the cells reached 70% confluence. After drug treatment, cells were trypsinized, collected by centrifugation. The cells were then resuspended in 200 μl of binding buffer (provided by the manufacturer). This buffer contained 5 μl of annexin V-FITC and propidium iodide (PI). The cells were incubated for 15 minutes at room temperature. All samples were kept on ice and analyzed immediately with a FACSCalibur flow cytometer (BD, USA).</p></sec><sec id="s2_4"><title>2.4. Animal Preparation</title><p>Forty Sprague-Dawley rats (approximately 4 months old and weighing 200 g) were divided into four groups, including a control group, a model group, a low dose group and a high dose group. The rats were anesthetized with 20% urethane (1300 mg/kg, i.p). The rats first were placed in a stereotaxic instrument with the incisor bar set 3 mm below the earbars (i.e., plat skull), and the scalp was incised and retracted. A hole was drilled in appropriate location in the skull with a dental drill. PAF (0.3 μg/kg, dissolved in artificial CSF, 5 μg/μl) was injected into the fourth ventricle. Eight control rats were injected with artificial CSF. The next day after operation, the low dose and high dose group rats were treated with BN52021. BN52021 was first dissolved in DMSO, and then PBS was added at the following concentrations (i.p.): 0.01 mol/L PBS, 1 mg/kg PBS (low dose), and 5 mg/kg PBS (high dose).</p></sec><sec id="s2_5"><title>2.5. Behavioral Testing</title><p>Behavioral testing began 6 days after injection (i.p.). The Morris water maze test was used to measure the rats’ ability to learn and remember spatial cues. The navigational test was conducted in a dark airtight room. The pool was divided into four quadrants, and a platform was placed in one of the quadrants. The rats were randomly placed in the water from four different directions. The rats were then allowed 90 seconds to find the platform. If the rats failed to find the platform within 90 seconds, they were placed on the platform where they stayed for 30 seconds. This test was conducted once per day for 4 days. The platform was then removed, and the rats were placed in the center of the pool to find the platform in order to test their special memory. A computer recorded (1) the number of times that the rat passed the platform and (2) the percentage of swimming distance in the platform quadrant to the total distance.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. The Cytotoxicity of PAF</title><p>MTT assay of cell viability showed that the absorbance value decreased gradually with the increase of PAF concentration. The absorbance value of 4 PAF concentration groups was shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Measurement of Apoptosis by Flow Cytometry was shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>: As the concentration of PAF increased, the percentage of apopotosis of cells increased.</p></sec><sec id="s3_2"><title>3.2. The Protection of BN52021 from PAF Cytotoxiciy</title><p>MTT Assay of Cell Viability to test PAF cytotoxicity was shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Both low dose and high dose of BN52021 could effectively increase light absorption of A value. Measurement of Apoptosis by Flow Cytometry was shown is <xref ref-type="fig" rid="fig4">Figure 4</xref>. Compared with PAF group, both low dose and high dose of BN52021 could decrease the percentage of apopotosis of cells.</p></sec><sec id="s3_3"><title>3.3. Morris Water Test of Spatial Memory</title><p>The rats appeared normal and did not lose weight following the PAF injection. The training results of the four tests in place navigation test (i.e., evasive latency) are shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>. The percentage of swimming distance in the platform quadrant relative to the total dis-</p><p>tance and the number of times the rats passed the platform are shown in <xref ref-type="fig" rid="fig6">Figure 6</xref>. The control group and the two treatment groups showed significant increases in both the number of times passing the platform and the percentage of the swimming distance, as compared to the model group.</p></sec></sec><sec id="s4"><title>4. Discussions</title><p>The primary mechanism associated with secondary brain injury is neuroinflammation and cerebral edema. Therefore, the inhibition of neuroinflammation likely represents a crucial therapy for the treatment of secondary brain injury [5,6]. As one of the strongest inflammatory factors,</p><p>PAF plays a key role in the modulation of neuroinflammation [<xref ref-type="bibr" rid="scirp.9081-ref7">7</xref>]. PAF is expressed in neurons as well as neuroglial cells, and previous studies report that PAF is increased after brain injury [<xref ref-type="bibr" rid="scirp.9081-ref8">8</xref>]. Therefore, a high dose of PAF could affect neurotoxicity [<xref ref-type="bibr" rid="scirp.9081-ref9">9</xref>]. Likewise, the PAFR antagonist-E5880 could protect neurons and neuroglial cells from neurotoxicity induced by glutamine [<xref ref-type="bibr" rid="scirp.9081-ref10">10</xref>].</p><p>In present study, PAF induced apoptosis and cell death when added to cultured PC12 cells. As the concentration of PAF increased, cell death increased in a similar manner. However, cell death markedly decreased when BN52021, a PAF antagonist, was administered prior to PAF. These findings demonstrate that BN52021 can protect PAF-induced cytotoxicity in vitro. Additionally, the central inflammatory response produced by the infusion of PAF produced a significant deficit in spatial memory,</p><p>as measured by the Morris water maze. Interestingly, this memory deficit was completely attenuated by the coadministration of BN52021. These results indicate that a PAFR antagonist protects neurons and neuroglial cells from neuroinflammation as well as spatial memory deficits. Therefore, PAFR antagonists may be a relevant compound for the treatment of brain injury, and BN52021 would be important to assess in clinical trials for brain injury.</p></sec><sec id="s5"><title>REFERENCES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.9081-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">X. D. Qu, R. Shrestha and M. D. Wang, “Risk Factors Analysis on Traumatic Brain Injury Prognosis,” Chinese Medical Sciences Journal, Vol. 26, No. 2, 2011, pp. 98-102. doi:10.1016/S1001-9294(11)60027-8</mixed-citation></ref><ref id="scirp.9081-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">J. M. Simard, Z. Geng, S. K. Woo, S. Ivanova, et al., “Glibenclamide Reduces Inflammation, Vasogenic Edema, and Caspase-3 Activation after Subarachnoid Hemorrhage,” Journal of Cerebral Blood Flow &amp; Metabolism, Vol. 29, No. 2, 2009, pp. 317-30.  
doi:10.1038/jcbfm.2008.120</mixed-citation></ref><ref id="scirp.9081-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">R. L. Wood and N. A. Rutterford, “Demographic and Cognitive Predictors of Long-Term Psychosocial Outcome Following Traumatic Brain Injury,” Journal of the International Neuropsychological Society, Vol. 12, No. 3, 2006, pp. 350-358. doi:10.1017/S1355617706060498</mixed-citation></ref><ref id="scirp.9081-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">W. L. Titsworth, N. K. Liu and X. M. Xu, “Role of Secretory Phospholipase a(2) in CNS Inflammation: Implications in Traumatic Spinal Cord Injury,” CNS Neurological Disorders—Drug Targets, Vol. 7, No. 3, 2008, pp. 254-269. doi:10.2174/187152708784936671</mixed-citation></ref><ref id="scirp.9081-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">X. Zhou, J. Zhou, X. Li, C. Guo, et al., “GSK-3β Inhibitors Suppressed Neuroinflammation in Rat Cortex by Activating Autophagy in Ischemic Brain Injury,” Biochemical and Biophysical Research Communications, Vol. 411, No. 2, 2011, pp. 271-275.  
doi:10.1016/j.bbrc.2011.06.117</mixed-citation></ref><ref id="scirp.9081-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">S. S. Dai and Y. G. Zhou, “Adenosine 2A Receptor: A Crucial Neuromodulator with Bidirectional Effect in Neuroinflammation and Brain Injury,” Review in the Neuroscience, Vol. 22, No. 2, 2011, pp. 231-239.  
doi:10.1515/RNS.2011.020</mixed-citation></ref><ref id="scirp.9081-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Y. Deng, W. Fang, Y. Li, et al., “Blood-Brain Barrier Breakdown by PAF and Protection by XQ-1H Due to Antagonism of PAF Effects,” European Journal of Pharmacology, Vol. 616, No. 1-3, 2009, pp. 43-47.  
doi:10.1016/j.ejphar.2009.06.017</mixed-citation></ref><ref id="scirp.9081-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">T. Tokutomi, H. Maruiwa, M. Hirohata, et al., “Production of Platelet-Activating Factor by Neuronal Cells in the Rat Brain with Cold Injury,” Neurological Research, Vol. 23, No. 6, 2001, pp. 605-611.  
doi:10.1179/016164101101199081</mixed-citation></ref><ref id="scirp.9081-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">H. S. Lustig, J. Chan and D. A. Greenberg, “Comparative Neurotoxic Potential of Glutamate, Endothelins, and Platelet-Activating Factor in Cerebral Cortical Cultures,” Neuroscience Letters, Vol. 139, No. 1, 1992, pp. 15-18.  
doi:10.1016/0304-3940(92)90847-Z</mixed-citation></ref><ref id="scirp.9081-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">S. Ishii and T. Shimizu, “Platelet-Activating Factor (PAF) Receptor and Genetically Engineered PAF Receptor Mutant Mice,” Progress in Lipid Research, Vol. 391, 2000, pp. 41-48. doi:10.1016/S0163-7827(99)00016-8</mixed-citation></ref></ref-list></back></article>